Literature DB >> 11774140

Serial magnetic resonance imaging evaluation of the patellar tendon after posterior cruciate ligament reconstruction.

Pier Paolo Mariani1, Fabrizio Margheritini, Gianluca Camillieri, Alberto Bellelli.   

Abstract

PURPOSE: Our purpose was to prospectively analyze serial changes in magnetic resonance imaging (MRI) signal of the bone-patellar tendon-bone autograft when used for posterior cruciate ligament (PCL) reconstruction and to retrospectively determine at mid-term follow-up the relationship between MRI graft appearance and clinical stability in patients who have undergone arthroscopic PCL reconstruction with a bone-patellar tendon-bone autograft. TYPE OF STUDY: One prospective serial blinded study and 1 retrospective blinded study.
METHODS: The first part of the study focused on MRI scans obtained at 3, 6, 9, and 12 months postoperatively in a case series of 10 consecutive patients who underwent arthroscopically assisted PCL reconstruction (group A), and of 10 patients who underwent combined ACL-PCL arthroscopic reconstruction (group B). For the second part of the study, MRI scans were obtained in a retrospective series of 10 patients at mid-term follow-up after PCL arthroscopic reconstruction (group C). Signal intensity of 3 zones, corresponding to the proximal, middle, and distal intra-articular graft zones, was evaluated according to the Howell et al. classification. Fiber continuity assessment was performed using a modified Kühne et al. score. The signal intensity of the 3 zones was independently scored. Knee stability was clinically and instrumentally graded according to the IKDC evaluation form (group 4). A multivariance analysis and grouped t test were used for statistical evaluation.
RESULTS: In group A, the average MRI evaluation score was 7.65 +/- 1.6 at 3 months, 3.8 +/- 0.6 at 6 months, 4.75 +/- 1 at 9 months and 6.25 +/- 1.2 at 1 year. The portion of graft exiting the femoral tunnel exhibited increased signal and faster maturation than the tibial tunnel. In group B (combined ACL-PCL reconstruction), the graft showed slower graft healing with an average MRI score of 4.85 +/- 0.7 at 3 months, 1.9 +/- 0.7 at 6 months, 3.9 +/- 0.9 at 9 months, and 5.3 +/- 1.1 at 1 year. At 1 year follow-up, there was no correlation between MRI appearance and stability in group A, even with MRI findings of fiber continuity. However, at long-term evaluation (group C), a strict correlation between MRI appearance and achieved stability was found.
CONCLUSIONS: The patellar tendon when used for PCL reconstruction requires more than 1 year to achieve a low-signal intensity over its entire course, and the distal zone near the tibial tunnel shows a slower healing process. MRI graft assessment is useful only 1 year or more following PCL reconstruction.

Entities:  

Mesh:

Year:  2002        PMID: 11774140     DOI: 10.1053/jars.2002.29937

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  4 in total

1.  Posterior cruciate ligament reconstruction using an arthroscopic femoral inlay technique.

Authors:  Fabrizio Margheritini; Francesco Frascari Diotallevi; Pier Paolo Mariani
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-03-16       Impact factor: 4.342

2.  MR imaging of stable posterior cruciate ligament grafts in 21 arthroscopically proven cases.

Authors:  Young Cheol Yoon; Hye Won Chung; Jin Hwan Ahn
Journal:  Korean J Radiol       Date:  2007 Sep-Oct       Impact factor: 3.500

Review 3.  [The killer turn in the posterior cruciate ligament reconstruction: mechanism and improvement].

Authors:  Yipeng Lin; Wufeng Cai; Xihao Huang; Jian Li; Qi Li
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-06-15

4.  Remnant preservation is helpful to obtain good clinical results in posterior cruciate ligament reconstruction: comparison of clinical results of three techniques.

Authors:  Sang Hak Lee; Young Bok Jung; Han-Jun Lee; Ho Joong Jung; Seong Hwan Kim
Journal:  Clin Orthop Surg       Date:  2013-11-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.